On Monday, in the course of current trade, Shares of eBay Inc. (NASDAQ:EBAY), gained 2.40%, and is now trading at $62.83, hitting its highest level.
eBay, declared the appointment of Daniel Tarman as eBay’s Chief Communications Officer following the separation of eBay and PayPal into two, independent publicly traded companies in the third quarter of 2015. Tarman will report to eBay CEO-designee Devin Wenig and become part of the company’s executive leadership team.
Tarman joins eBay from PIMCO, where for the past eight years he served as Executive Vice President and Global Head of Corporate Communications. Reporting to the CEO, Tarman led brand and reputation administration efforts for PIMCO, the world’s largest bond investment administration firm, with $1.6 trillion in assets under administration. Preceding to PIMCO, Tarman held senior communications positions at Countrywide Financial Corporation, VISA, and the global public relations agency Burson-Marsteller. Tarman holds a bachelor’s degree from Tulane University and a law degree from the University of Miami.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally. It operates in three segments: Marketplaces, Payments, and Enterprise.
During an Afternoon trade, Shares of Johnson & Johnson (NYSE:JNJ), gained 0.11%, and is now trading at $100.25.
An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday, according to Reuters.
J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and Drug Administration, which can assist speed the approval process.
Nearly 30 percent of 106 patients responded to daratumumab, counting 3 complete responses, meaning no sign of cancer. Another 10 patients had a very good partial response defined as 90 percent reduction of myeloma protein in the blood or urine, while 18 had a partial response, researchers stated, Reuters Reports.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Shares of Prima Biomed Ltd. (NASDAQ:PBMD), during its Monday’s current trading session fell -16.23%, and is now trading at $1.91.
Prima BioMed, declared that it has made substantial progress with its lead product, IMP321.
- Prima advises that it has filed for patent protection over the use of IMP321 in conjunction with checkpoint inhibitor molecules, which the company believes gives IMP321 noteworthy clinical and commercial advantages.
- Prima’s CEO, Marc Voigt, and CSO & CMO, Professor Frédéric Triebel, will be attending the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago to talk about IMP321 with key opinion leaders in the immuno-oncology field.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
Finally, GameStop Corp. (NYSE:GME), gained 0.16% Monday.
GameStop, stated sales and earnings for the first quarter ended May 2, 2015.
Q1 2015 Financial Summary
Total global sales rose 3.2% to $2.06 billion (an 8.1% enhance in constant currency) primarily driven by 9.6% growth (a 15.8% enhance in constant currency) in new software sales. The company captured noteworthy market share of the key quarterly title releases, leading to record first quarter new software market share of 45%. The Pre-owned category declined 3.4%; however, it raised 0.8% in constant currency.
Merged comparable store sales raised 8.6% (+9.1% in the U.S. and +6.9% internationally), led by double digit same store sales enhances in Australia and Canada.
Non-GAAP digital receipts raised 17.2% (a 23.3% enhance in constant currency) to $222.2 million, or $46.0 million of sales on a GAAP basis. Strong sales of downloadable content for new releases, such as Evolve and Mortal Kombat X, together with enhances in mobile game downloads and Steam currency, were the primary growth drivers during the quarter.
Sales in the mobile and consumer electronics category rose 33.9% (a 34.6% enhance in constant currency) to $136.8 million. Technology Brands revenues raised 70% to $102.2 million, driven by the addition of 65 new stores during the first quarter. As a result of these openings, Spring Mobile is now AT&T’s second largest authorized reseller in the United States.
Net earnings exceeded the high-end of guidance, increasing 8.5% to $73.8 million, or $0.68 per diluted share, contrast to net earnings of $68.0 million, or $0.59 per diluted share, in the preceding year quarter. For the first quarter of 2015, diluted earnings per share raised 15.3% contrast to the preceding year quarter. The $73.8 million of earnings represents the highest level of profitability in a first quarter since the first quarter of 2011. Foreign currency exchange rate changes did not materially impact earnings results for the first quarter.
GameStop Corp. operates as a multichannel video game retailer. It sells new and pre-owned video game hardware; physical and digital video game software; pre-owned and value video game products; video game accessories, such as controllers, gaming headsets, memory cards, and other add-ons for use with video game hardware and software; and digital products, counting downloadable content, network points cards, prepaid digital and online timecards, and digitally downloadable software.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
